Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Dose Finding Study Followed by Phase II Randomized, Placebo-Controlled Study of Veliparib (ABT-888) Added to Chemoradiotherapy With Carboplatin and Paclitaxel for Unresectable Stage III Non-small Cell Lung Cancer (NSCLC), (NCI Study Number 8811)

Next Previous
Trial Profile

A Dose Finding Study Followed by Phase II Randomized, Placebo-Controlled Study of Veliparib (ABT-888) Added to Chemoradiotherapy With Carboplatin and Paclitaxel for Unresectable Stage III Non-small Cell Lung Cancer (NSCLC), (NCI Study Number 8811)

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 24 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Veliparib (Primary) ; Carboplatin; Paclitaxel
  • Indications Adenocarcinoma; Bronchiolo-alveolar adenocarcinoma; Large cell carcinoma; Non-small cell lung cancer; Squamous cell cancer
  • Focus Adverse reactions; Therapeutic Use

Most Recent Events

  • 03 Feb 2025 Planned End Date changed from 31 Dec 2024 to 31 Dec 2025.
  • 12 Jan 2024 Planned End Date changed from 31 Dec 2023 to 31 Dec 2024.
  • 28 Jan 2023 Planned End Date changed from 31 Dec 2022 to 31 Dec 2023.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top